← Back to headlines
Summit Therapeutics Reveals Phase II AK112-206 Trial Data
Summit Therapeutics (SMMT) has disclosed data from its Phase II AK112-206 clinical trial, providing an update on the drug's development and efficacy.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
BASF Files Patent Infringement Lawsuit Against Apple Over Face Authentication Tech
12m ago
Adobe Appoints Anil Chakravarthy as Chief Executive Officer Amid Leadership Transition
15m ago
Volkswagen Announces Plan to Cut 100,000 Jobs by 2030
33m ago
Vice President Vance Downplays Iran Conflict, Declines to Label It a War
46m ago